New Dual-Target CAR t therapy shows promise for Hard-to-Treat multiple myeloma

NCT ID NCT06235229

Recruiting now Disease control Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated Apr 23, 2026 · Updated 19 times

Summary

This study tests a new treatment called GC012F for people with multiple myeloma that has returned or not responded to at least three prior therapies. GC012F uses a patient's own immune cells, modified to target two proteins (CD19 and BCMA) on cancer cells, to attack the disease. The trial aims to find the safest dose and measure how well the treatment shrinks tumors, with 110 participants enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
ACTIVE_NOT_RECRUITING

Beijing, 100024, China
Research Site
RECRUITING

Beijing, 102200, China
Research Site
RECRUITING

Hangzhou, 310003, China
Research Site
RECRUITING

Jinan, 250117, China
Research Site
RECRUITING

Shanghai, 200003, China
Research Site
RECRUITING

Shanghai, 201210, China
Research Site
RECRUITING

Shenyang, 110134, China
Research Site
RECRUITING

Wenzhou, 325000, China
Research Site
RECRUITING

Wuhan, 430030, China
Research Site
ACTIVE_NOT_RECRUITING

Xi'an, 710004, China

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA